Background The optimal perioperative antithrombotic strategy for patients with acute
coronary syndrome (ACS) during percutaneous coronary intervention (PCI) remains …

Objective Current guidelines recommend potent P2Y12 inhibitors such as ticagrelor over
clopidogrel as part of the dual antiplatelet therapy (DAPT) after ST-segment elevation …

Background It remains unknown if bivalirudin compared to heparin confers any additional
inhibition of platelet and coagulation activation during primary percutaneous coronary …

Objectives: This study sought to determine if the efficacy of bivalirudin alone versus heparin
plus a glycoprotein (GP) IIb/IIIa inhibitor is dependent upon the duration of clopidogrel pre …

Objective: The aim of this study was to investigate the safety and efficacy of bivalirudin plus
ticagrelor compared with heparin plus clopidogrel in patients with ST-segment elevation …

Objectives: This study sought to investigate if the efficacy of bivalirudin monotherapy is
similar to heparin plus GP IIb/IIIa inhibition in patients with acute coronary syndromes (ACS) …

• The Bivalirudin With Prolonged Full-Dose Infusion During Primary PCI Versus Heparin
Trial (BRIGHT)-4 trial was an investigator-initiated, open-label, randomized controlled trial …

Background Multiple antithrombotic options are available for patients undergoing primary
percutaneous coronary interventions for stent thrombosis elevation acute myocardial …

Aim: Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment
to prevent thrombotic complications of acute coronary syndromes and percutaneous …

Although clopidogrel pretreatment benefits patients undergoing percutaneous coronary
intervention (PCI) for acute coronary syndromes, these benefits are less well established …